Full Press Release Details
FORT MILL, S.C., Feb. 05, 2026 (GLOBE NEWSWIRE) --Catheter Precision, Inc. (NYSE American: VTAK), a pioneer in medical technology for the cardiac electrophysiology market, today announced that its LockeT suture retention device will be highlighted during live procedural cases at theStructural Heart Intervention and Imaging: A Practical Approach 2026conference. The event, hosted by Scripps Health, will take place from February 11–13,2026, at the Hyatt Regency La Jolla at Aventine in San Diego.
The Scripps Structural Heart course is a premier educational forum featuring state-of-the-art, live case-based reviews of structural heart disease interventions and cardiovascular imaging. Leading interventional cardiologists from across the country are presenting at the conference and the inclusion of LockeT in live cases underscores the device's growing role in streamlining workflow efficiency and enhancing patient recovery after venous catheter access.
“We are honored to have LockeT showcased at such a prestigious clinical gathering,” said David Jenkins, CEO ofCatheter Precision. “As we enter 2026 with strong momentum and expansion into major medical centers likeScripps in Southern California, these live cases provide a vital platform for physicians to witness firsthand the operational and economic advantages of our suture retention technology.”
About LockeTCatheter Precision’sLockeTis a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About Catheter PrecisionCatheter Precisionis an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking StatementsStatements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS: